aibio
Financings ·
Protalix renews $20,000,000 at-the-market stock program with H.C. Wainwright
About $15.7 million of stock remains available for sale after earlier sales of $4.3 million. The sales agent earns a 3.0% commission.
PLX Protalix BioTherapeutics, Inc. (DE)
Protalix BioTherapeutics, Inc. (DE) (PLX) news PLX class action and offering news
Latest Protalix BioTherapeutics, Inc. (DE) news
- Legal
Protalix says Delaware stockholder class action over bylaws is dismissed, $160,000 in counsel fees
A Delaware stockholder class action against Protalix BioTherapeutics and its board, Thomas v. Bashan, et al., was dismissed as to the plaintiff after the board amended the bylaws. Protalix agreed to pay $160,000 in fees and expenses to the plaintiff's counsel, and it denies the allegations.
What Protalix BioTherapeutics, Inc. (DE) does
Protalix BioTherapeutics is a commercial stage biopharmaceutical company focused on the discovery, development, production and commercialization of therapeutics for rare diseases with significant unmet needs. Its proprietary ProCellEx plant cell-based protein expression system is used to manufacture its approved products and its pipeline candidates. The company's two commercial products are enzyme replacement therapies: Elelyso, for Gaucher disease, and Elfabrio, for Fabry disease. Elelyso was approved by the FDA in 2012 and is approved in more than 40 markets. Pfizer holds worldwide rights to commercialize Elelyso other than in Brazil, where Fiocruz markets it as BioManguinhos alfataliglicerase. In March 2026 the European Commission ratified a positive opinion approving the 2 mg/kg E4W dosing regimen of pegunigalsidase alfa for Fabry disease, after an appeal of an October 2025 negative opinion. The company is turning its focus to early-stage candidates for renal diseases and other high unmet need indications, including PEGylated uricase PRX-115 for uncontrolled gout, which is in a Phase 2 RELEASE study after a Phase 1 first-in-human trial, and long-acting DNase I PRX-119 for NETs-related diseases.
| Product or program | What it is | Stage |
|---|---|---|
| Elelyso (taliglucerase alfa) | Plant cell-derived enzyme replacement therapy for Gaucher disease | approved in more than 40 markets |
| Elfabrio (pegunigalsidase alfa) | Enzyme replacement therapy for adults with a confirmed diagnosis of Fabry disease | commercial product |
| PRX-115 | PEGylated uricase for uncontrolled gout | Phase 2 (RELEASE), patients randomized |
| PRX-119 | Long Acting DNase I for NETs-related diseases |
Protalix BioTherapeutics, Inc. (DE) annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $52.7 million | $53.4 million |
| Research and development | $19.6 million | $13.0 million |
| Net income (loss) | -$6.6 million | $2.9 million |
| Cash from operations | -$12.0 million | $8.7 million |
| Cash and equivalents | $14.7 million | $19.8 million |
Analysis
Opinion Mixed view
Protalix has about a year of cash on paper. The second year is less clear.
Two approved drugs and an early pipeline. The company has $40.7 million and says that lasts 12 months, but its own filing lists 24 months of cash needs.
Questions about Protalix BioTherapeutics, Inc. (DE)
Is there a class action against Protalix BioTherapeutics, Inc. (DE)?
Our latest story on this, dated Aug 1, 2025: "Protalix says Delaware stockholder class action over bylaws is dismissed, $160,000 in counsel fees". The story links the filing or release it is based on. Read the story.
Has Protalix BioTherapeutics, Inc. (DE) raised money recently?
Our latest story on this, dated Aug 22, 2025: "Protalix renews $20,000,000 at-the-market stock program with H.C. Wainwright". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Protalix BioTherapeutics, Inc. (DE)?
Protalix BioTherapeutics, Inc. (DE) trades under the ticker PLX on AMEX.
Where is Protalix BioTherapeutics, Inc. (DE) listed?
Protalix BioTherapeutics, Inc. (DE) is listed on AMEX. Our directory also records these other listings: GETTEX:PBDA; LSX:A2PWSL.
What is the SEC CIK of Protalix BioTherapeutics, Inc. (DE)?
The SEC Central Index Key (CIK) for Protalix BioTherapeutics, Inc. (DE) is 1006281. Its filings are on SEC EDGAR.
How many shares does Protalix BioTherapeutics, Inc. (DE) have outstanding?
80,571,642 shares as of 2026-08-01, per the cover page of its 10-Q filed 2026-08-12.
Which country or territory is Protalix BioTherapeutics, Inc. (DE) listed under?
Our directory records Protalix BioTherapeutics, Inc. (DE) under United States.
What does Protalix BioTherapeutics, Inc. (DE) do?
Our directory classifies Protalix BioTherapeutics, Inc. (DE) as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Protalix BioTherapeutics, Inc. (DE)?
The ISIN recorded for Protalix BioTherapeutics, Inc. (DE) is US74365A3095.
Does aibio.space cover Protalix BioTherapeutics, Inc. (DE)?
aibio.space lists Protalix BioTherapeutics, Inc. (DE) among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Protalix BioTherapeutics, Inc. (DE) incorporated?
SEC records list its state or country of incorporation as DE.
What does Protalix BioTherapeutics, Inc. (DE) develop?
Protalix BioTherapeutics is a commercial stage biopharmaceutical company focused on the discovery, development, production and commercialization of therapeutics for rare diseases with significant unmet needs. Its proprietary ProCellEx plant cell-based protein expression system is used to manufacture its approved products and its pipeline candidates.
What is Elelyso (taliglucerase alfa) from Protalix BioTherapeutics, Inc. (DE)?
Elelyso (taliglucerase alfa): Plant cell-derived enzyme replacement therapy for Gaucher disease Stage: approved in more than 40 markets.
What is Elfabrio (pegunigalsidase alfa) from Protalix BioTherapeutics, Inc. (DE)?
Elfabrio (pegunigalsidase alfa): Enzyme replacement therapy for adults with a confirmed diagnosis of Fabry disease Stage: commercial product.
What was Protalix BioTherapeutics, Inc. (DE)'s revenue last year?
$52.7 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Investor discussion: Protalix BioTherapeutics, Inc. (DE)
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
SEC filings and registration
- SEC name
- Protalix BioTherapeutics, Inc.
- CIK
- 1006281
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- PLX (NYSE)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 2 UNIVERSITY PLAZA, HACKENSACK, NJ, 07601
- Phone
- 201-696-9345
- Shares outstanding
- 80,571,642 as of 2026-08-01 (10-Q filed 2026-08-12)
- Former names
- ORTHODONTIX INC; EMBASSY ACQUISITION CORP
Recent filings
Listing details
- Company
- Protalix BioTherapeutics, Inc. (DE)
- Ticker
- PLX
- Listing
- AMEX
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US74365A3095
- Other listed symbols
- GETTEX:PBDA; LSX:A2PWSL
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction